Molecular approaches for new vaccines against allergy

Type I allergy represents an important health problem that is currently affecting approximately 25% of the population in Western countries. Immunotherapy, the only causative treatment of Type I allergy, is currently performed with crude allergen extracts, which contain unpredictable amounts of allergenic, as well as nonallergenic, components. The application of molecular biology for allergen characterization has revealed the molecular nature of the most common allergens and allowed the production of recombinant allergens that equal natural allergens. Based on this knowledge, several different strategies to improve immunotherapy have become available. Until now, T-cell peptides, selected wild-type-like recombinant allergens and genetically modified hypoallergenic allergen derivatives have been evaluated in clinical trials in patients. Immunotherapy based on T-cell peptides has focused on allergen-specific T-cell responses, whereas genetically modified recombinant allergen molecules offer the advantage of combining T-cell and B-cell epitopes. Genetically modified recombinant birch pollen derivatives (Bet v 1-fragments, Bet v 1-trimer) have been evaluated in a double-blind, placebo-controlled, multicenter study. Vaccination with the Bet v 1-derivatives improved symptoms of birch pollen allergy, induced a healthy allergen-specific immunoglobulin G response and led to a significant reduction of seasonally induced boosts of immunoglobulin E.

[1]  M. Jutel,et al.  Allergen-specific immunotherapy with recombinant grass pollen allergens. , 2005, The Journal of allergy and clinical immunology.

[2]  C. Akdis,et al.  Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 , 2005, International Archives of Allergy and Immunology.

[3]  Franz König,et al.  Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. , 2005, The Journal of allergy and clinical immunology.

[4]  N. Reider.  Sublingual Immunotherapy for Allergic Rhinoconjunctivitis – The Seeming and the Real , 2005, International Archives of Allergy and Immunology.

[5]  S. Ying,et al.  Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  H. Grönlund,et al.  Vaccination with genetically engineered allergens prevents progression of allergic disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Valenta,et al.  Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  A. Kay,et al.  Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study , 2004, Allergy.

[9]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[10]  R. Valenta,et al.  Component‐resolved diagnosis of house‐dust mite allergy with purified natural and recombinant mite allergens , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  M. Marinaro,et al.  The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  Adriano Mari,et al.  The allergome web site - a database of allergenic molecules. Aim, structure, and data of a web-based resource , 2004 .

[13]  C. Ebner,et al.  Allergen‐specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy , 2003, Immunology.

[14]  R. Valenta,et al.  Renaissance of the Blocking Antibody Concept in Type I Allergy , 2003, International Archives of Allergy and Immunology.

[15]  R. Valenta,et al.  Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  H. Breiteneder,et al.  Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice , 2003, Clinical and experimental immunology.

[17]  J. Slater,et al.  Endotoxin content of standardized allergen vaccines. , 2003, The Journal of allergy and clinical immunology.

[18]  M. Audícana,et al.  Systemic reactions to immunotherapy: influence of composition and manufacturer , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  F. Spertini,et al.  Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. , 2003, The Journal of allergy and clinical immunology.

[20]  M. A. Costa,et al.  The Allergens of Parietaria , 2003, International Archives of Allergy and Immunology.

[21]  G. Canonica,et al.  Noninjection routes for immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[22]  J. Lidholm,et al.  Characteristics and Immunobiology of Grass Pollen Allergens , 2003, International Archives of Allergy and Immunology.

[23]  R. Valenta,et al.  From allergen structure to new forms of allergen-specific immunotherapy. , 2002, Current opinion in immunology.

[24]  H. Vijay,et al.  Immunobiology of Fungal Allergens , 2002, International Archives of Allergy and Immunology.

[25]  M. Andersson,et al.  Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild‐type in patients with allergic rhinitis , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  A. Kay,et al.  Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial , 2002, The Lancet.

[27]  W. Thomas,et al.  Characterization and Immunobiology of House Dust Mite Allergens , 2002, International Archives of Allergy and Immunology.

[28]  R. Valenta.  The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.

[29]  R. Valenta,et al.  Specific immunotherapy – the induction of new IgE‐specificities? , 2002, Allergy.

[30]  T. Haahtela,et al.  Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™ , 2002, Allergy.

[31]  R. Valenta,et al.  Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy1 , 2002, The Journal of Immunology.

[32]  J. Lidholm,et al.  Recombinant Marker Allergens: Diagnostic Gatekeepers for the Treatment of Allergy , 2002, International Archives of Allergy and Immunology.

[33]  Wayne Thomas,et al.  Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  R. Esch,et al.  Major allergen measurements: sources of variability, validation, quality assurance, and utility for laboratories, manufacturers, and clinics. , 2002, Allergy and asthma proceedings.

[35]  B. Niggemann,et al.  Evolution of IgM, IgE and IgG1–4 antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms , 2002, European journal of immunology.

[36]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[37]  R. Lockey.  "ARIA": global guidelines and new forms of allergen immunotherapy. , 2001, The Journal of allergy and clinical immunology.

[38]  P. Hufnagl,et al.  Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  M. Villalba,et al.  The Spectrum of Olive Pollen Allergens , 2001, International Archives of Allergy and Immunology.

[40]  R. Valenta,et al.  Recombinant allergen molecules: tools to study effector cell activation , 2001, Immunological reviews.

[41]  T. P. King,et al.  Structure and Biology of Stinging Insect Venom Allergens , 2000, International Archives of Allergy and Immunology.

[42]  Oster,et al.  Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[43]  H. Breiteneder,et al.  Molecular and biochemical classification of plant-derived food allergens. , 2000, The Journal of allergy and clinical immunology.

[44]  Jarman,et al.  Short‐term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T‐cell responses, in patients with allergic rhinitis , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[45]  J. Lamb,et al.  Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. , 1999, Journal of immunology.

[46]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[47]  R. Valenta,et al.  Genetically Engineered and Synthetic Allergen Derivatives: Candidates for Vaccination against Type I Allergy , 1999, Biological chemistry.

[48]  Niederberger,et al.  The recombinant allergen‐based concept of component‐resolved diagnostics and immunotherapy (CRD and CRIT) , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[49]  B. Haselden,et al.  Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic Reactions , 1999, The Journal of experimental medicine.

[50]  H. Renz,et al.  Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. , 1999, The Journal of allergy and clinical immunology.

[51]  C. Akdis,et al.  IL‐10‐induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  H. Breiteneder,et al.  Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[54]  R. Valenta,et al.  Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. , 1998, The Journal of allergy and clinical immunology.

[55]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[56]  R. Valenta,et al.  Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. , 1998, Journal of immunology.

[57]  C. Akdis,et al.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.

[58]  H. Karjalainen,et al.  Recombinant allergen fragments as candidate preparations for allergen immunotherapy. , 1997, The Journal of allergy and clinical immunology.

[59]  R. Valenta,et al.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.

[60]  F. Simons,et al.  Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. , 1996, International immunology.

[61]  R. Van Ree,et al.  False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. , 1996, The Journal of allergy and clinical immunology.

[62]  D. Golden,et al.  Discontinuing venom immunotherapy: outcome after five years. , 1996, The Journal of allergy and clinical immunology.

[63]  U Ackermann-Liebrich,et al.  Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. , 1995, International archives of allergy and immunology.

[64]  R. O’Hehir,et al.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice , 1993, The Journal of experimental medicine.

[65]  J. Greenstein,et al.  Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[67]  M. Breitenbach,et al.  IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa* , 1989, Allergy.

[68]  R. Valenta,et al.  The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. , 1989, The EMBO journal.

[69]  H. Løwenstein,et al.  Isolation and immunochemical characterization of the major allergen of birch pollen (Betula verrucosa). , 1983, The Journal of allergy and clinical immunology.

[70]  P. Holt,et al.  Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. , 1981, Immunology.

[71]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.

[72]  K. Mathews.  Immunotherapy for allergic disease. , 1976, Comprehensive therapy.

[73]  D. Marsh.  Preparation and properties of ,allergoids, derived from native pollen allergens by mild formalin treatment. , 1971, International archives of allergy and applied immunology.

[74]  이현주,et al.  ADRENOCORTICOTROPIC hormone. , 1951, Lancet.